Funding for this research was provided by:
National Institute for Health Research (RM-FI-2017-08-027, NF-SI-0512-10159)
Medical Research Council (MR/R025223/1, MR/R025223/1)
Article History
Received: 13 November 2020
Accepted: 21 April 2021
First Online: 3 June 2021
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: JS does not have conflict of interest.SB has served as a paid consultant, providing methodological advice, to NICE and Roche, and has received research funding from European Federation of Pharmaceutical Industries & Associations (EFPIA) and Johnson & Johnson.KRA has served as a paid consultant, providing methodological advice, to; Abbvie, Amaris, Allergan, Astellas, AstraZeneca, Boehringer Ingelheim, Bristol-Meyers Squibb, Creativ-Ceutical, GSK, ICON/Oxford Outcomes, Ipsen, Janssen, Eli Lilly, Merck, NICE, Novartis, NovoNordisk, Pfizer, PRMA, Roche and Takeda, and has received research funding from Association of the British Pharmaceutical Industry (ABPI), European Federation of Pharmaceutical Industries & Associations (EFPIA), Pfizer, Sanofi and Swiss Precision Diagnostics. He is a Partner and Director of Visible Analytics Limited, a healthcare consultancy company.